Skip to main content

Table 3 Direct and non-direct costs variability intra country per patient according to phase of the disease and lymphocytes level (€ 2010)

From: Economic impact of HIV/AIDS: a systematic review in five European countries

Total healthcare costs Spain (n* = 9) Germany (n* = 3) France(n* = 4) Italy (n* = 17) United Kingdom (n* = 15)
n MEAN SD MIN MAX n MEAN SD MIN MAX n MEAN SD MIN MAX n MEAN SD MIN MAX n MEAN SD MIN MAX
According to phase of the disease (**)
Asymptomatic phase 1 8.547,53 - - - 0 - - - - 0 - - - - 1 2.173,9 - - - 5 1.4991,73 3.493,29 10.571,45 18.290,76
Symptomatic phase 1 10.173,81 - - - 0 - - - - 0 - - - - 0 - - - - 5 19.222,25 4.437,73 12.131,42 22.945,24
AIDS phase 2 11.032,38 1.058,39 10.272,01 11.768,99 0 - - - - 0 - - - - 1 15.182,96 - - - 5 42.968,55 12.487,71 23.155,18 53.241,22
According to lymphocytes level (CD4 cells)
CD4s < 200 0 - - - - 0 - - - - 0 - - - - 3 19.252,63 5.840,26 15.182,96 25.944,39 3 49.326,37 6.250,58 42.117,73 53.241,22
200 < CD4s < 500 3 9.922,42 750,11 8.849,42 10.272,01 3 32.109,62 6.960,48 26.650,64 39.041,96 1 13.396,55 - - - 2 12.227,88 2.062,68 9.670,24 13.059,63 9 21.445,86 9.572,81 11.889,08 45.811,29
CD4s > 500 0 - - - - 0 - - - - 0 - - - - 3 6.399,34 2.369,71 2.173,9 10.363,14 0 - - - -
  1. * = number of cost estimates included in the analysis; and, ** = there are some studies that do not specify the phase of the disease from patients.